Tripla XR Tablets 25 mg / 5 mg / 1000 mg and 12.5 mg / 2.5 mg / 1000 mg

Tripla XR is an oral fixed-dose combination indicated for the management of type 2 diabetes mellitus. It combines three complementary mechanisms of action to improve glycaemic control in adult patients. Empagliflozin is a sodium-glucose co-transporter-2 (SGLT2) inhibitor that reduces renal glucose reabsorption and promotes urinary glucose excretion. Linagliptin is a dipeptidyl peptidase-4 (DPP-4) inhibitor that enhances incretin hormone activity, improving glucose-dependent insulin secretion. Metformin decreases hepatic glucose production and improves peripheral insulin sensitivity. Tripla XR offers comprehensive glycaemic management through synergistic action in a convenient extended-release oral formulation.